Startup Rise America News’ Post

!!We Are NOBiotics!! Building a medical biotechnology firm from scratch isn’t just about science—it’s about purpose. At NOBiotics, we’re on a mission to tackle incurable diseases , driven by the families who need solutions today. Our work isn’t lip service. With cutting-edge research and real-world impact, we develop therapies and devices that truly transform lives. Every step we take is about easing suffering and making a tangible difference. We dream big, act boldly, and focus on people over profits. Together, we are NOBiotics—committed to changing lives, one breakthrough at a time. NOBiotics www.nitricoxide.life #biomedicaltechnology #biotechnology #investors #VC #startup #angelinvestors #funding #biomedicaldevices #RTP

🚀Biotechnology: The Engine Driving Medical Advancements🚀 What's the future of life science like, and what are the advantages of the MAxL incubator? In the latest edition of VentureCapital Magazin, Christian Gnam (IZB - Innovation and Start-up Center Biotechnology) and Ralf Huss (BioM Biotech Cluster Development GmbH) answer these questions and share insights on how #MAxL drives biotech advancements, enhances partnerships, and offers new opportunities in the biotech landscape.📈 📖 Find out more: https://lnkd.in/d6JwUvUc #Biotechnology #IZB #Startup #CampusMartinsried

Overall, more #money for German #biotechnology companies – but early financing remains difficult for startups from the sector. The complete analysis with numerous exciting results and insights: https://lnkd.in/dwGh77FC #EYbiotech #BetterQuestions #BetterAnswers

Overall, more #money for German #biotechnology companies – but early financing remains difficult for startups from the sector. The complete analysis with numerous exciting results and insights: https://lnkd.in/ehzDUug8 #EYbiotech #BetterQuestions #BetterAnswers

Overall, more #money for German #biotechnology companies – but early financing remains difficult for startups from the sector. The complete analysis with numerous exciting results and insights: https://lnkd.in/dFvknKDW #EYbiotech #BetterQuestions #BetterAnswers

Live from #ATW25, Kerstin Dolph discusses the launch of Charles River’s Incubator Program, designed to help early-stage developers overcome this translation hurdle, with scientific advisory services and capabilities to bolster programs from concept to cure. Explore the benefits: https://bit.ly/40tN4qi Learn more about the program: https://bit.ly/4apDxVO

Discover the different types of partnerships in biotechnology! 🤝 We know that strategic collaborations are essential for innovation and progress in the biotechnology field. This blog from #Labiotech.eu explores the various forms of partnerships that can propel #biotech companies to new heights. Whether you are a startup or an established company, understanding these dynamics can help you maximize your potential and accelerate your projects. 🌱💡 📝 Blog: The ABC of biotech partnerships 🔗 Link: https://lnkd.in/eW8Utykz #Biotechnology #Innovation #Partnerships #Collaboration #Research #Development

Integrated Biosciences Secures $17.2 Million to Develop Medicines for Age-Related Diseases Integrated Biosciences, Inc., a California-based biotechnology startup pioneering medicines targeting age-related illnesses, has secured $17.2 million in seed funding to advance treatment for healthier aging. Co-founded in September 2022 by Felix Wong and Max Wilson, the company develops cellular rejuvenation therapies using a combination of small molecules and optogenetics. The seed round was backed by a consortium of companies spearheaded by Sutter Hill Ventures, with significant contributions from notable investors, including Root Ventures, llumina Ventures Labs, Civilization Ventures, Lifespan Vision Ventures, SH funds (Sabrina Hahn), Overlap Holdings, Conscience VC, Reinforced Ventures, Mission BioCapital, Polymath Capital, Vijay Pandurangan and Michael Stoppelman. Read more: https://lnkd.in/gWHvZu5M #fundingnews #FundingOpportunity #StartupFunding #StartupSuccess #HealthcareNews #Biotechnology #HealthcareFunding #nextdigitalhealth #Wi4 #vineetagrawal

🌟 Advanced Therapies Week Highlight: Launch of Charles River's Global Biotech Incubator Program 🌟 Join Kerstin Dolph, Senior VP of Manufacturing at Charles River Laboratories, and host Benjamin McLeod from Convey Bio for an exciting introduction to the Charles River Incubator Program (CIP). This pioneering program supports the journey of early-stage biotechnology companies in the development of advanced therapies. The CIP is dedicated to nurturing startups by offering regulatory guidance, quality expertise, personnel training, and access to laboratory facilities, all aimed at enhancing their path to commercial success. Discover how your biotech venture can apply and benefit from this unique opportunity to accelerate growth and innovation. #AdvancedTherapiesWeek #ATW25 #AdvancedTherapies #CharlesRiver #BiotechIncubator

Biotechgate monthly report provides a summary of biotech financing in May 2024, highlighting trends, investment values, and notable funding rounds in the life science industry. In May 2024, private equity investment in the biotech sector saw a decline in both total value and number of financing rounds compared to April 2024, with notable variations across different regions. The sector's total investment value decreased from USD 3.3bn in April to USD 2.5bn in May, indicating a cautious approach or a possible reallocation of funds by investors. The number of financing rounds dropped slightly from 70 to 63, suggesting fewer investment opportunities or a more selective strategy. Most financing rounds in May 2024 continued to target US-based biotech companies, though there was a slight decrease in investment value (April: USD 2.6bn vs. May: USD 2.2bn) and a slight increase in the number of rounds (April: 31 vs. May: 35), indicating a broader spread of smaller investments. In Europe, the aggregated investment value decreased from USD 371m to USD 311m, with the number of rounds dropping from 20 to 18. The Rest of the World saw a significant decline in investment value from USD 329m to USD 174m, and the number of rounds fell from 21 to 12, highlighting a more pronounced pullback in investments outside the US. Funding rounds below USD 5m and those surpassing USD 30m each contributed almost equally to the total funding landscape, at 33% each. In terms of the allocation of funds for these deals, among deals over USD 30m, 5% were Seed rounds, 24% were Series A rounds, with Series B and C rounds each contributing 29%. For deals under USD 5m, 19% were Seed rounds, 24% were Series A, and 5% were Series B rounds. Additionally, transactions within the USD 5m to 15m range accounted for 22%, and rounds between USD 15 and 30m represented 11%. #biotech #biotechfunding #ipobiotech #healthcare #pharmainnovation https://lnkd.in/gibXmpCu